Skip to main content

The Money Overview

About 22% of stand-alone Medicare drug plan members are in four-star contracts for 2027, up from 2%

The Centers for Medicare & Medicaid Services (CMS) says about 22% of people in stand-alone Medicare drug plans will be in contracts rated four stars or higher for 2027, up from about 2% for 2026. The agency published the ratings in an October 8 fact sheet, a week before open enrollment opens on October 15. Among Medicare Advantage plans that include drug coverage, the share is about 71%. Both figures are weighted by enrollment, so they count people, not contracts, and a star rating is a quality score that says nothing about what a plan costs.

The question for a member of a stand-alone drug plan, or of a Medicare Advantage plan with drug coverage, is whether a higher rating means a better deal on their own prescriptions. It does not settle that. The rating covers a whole contract, which can include many plans in many counties, and it grades measures such as appeals handling and medication safety. Whether one plan covers one drug at one price for 2027 is a separate check, and it decides what a member pays from January 1.

Only about 22% of stand-alone drug plan members are in a four-star contract, and the rating still says nothing about what one prescription costs on one plan. The 2027 Medicare Open Enrollment Decision Kit includes a prescription-by-plan comparison that sets each plan’s cost against a member’s own drug list.

Price each 2027 drug plan against one prescription list with the Open Enrollment Decision Kit →

Stand-alone drug plans: from 2% to 22%

CMS’s 2027 Star Ratings fact sheet counts 41 stand-alone prescription drug plan contracts, and 11 of them, about 27%, earned four stars or more. Weighted by enrollment, those contracts hold about 22% of members, which CMS compares with about 2% in 2026. The highest-rated contracts are therefore a little smaller than average, and most people in stand-alone plans remain in contracts rated below four stars.

The average moved less than the headline share. CMS reports an enrollment-weighted Part D rating of 3.22 for stand-alone plans in 2027, up from 3.01 in 2026 and 3.12 in 2025, though still below the 3.34 of 2024. The fact sheet does not name which contracts crossed the four-star line. It does say CMS recalculates the cut points between star levels every year from the performance measured that year, so the lines themselves move from one rating cycle to the next.

Ratings are not prices. CMS’s September 28 landscape release puts the average monthly premium for a stand-alone drug plan at $36 for 2027, up from $35.09 in 2026, an increase of under $1. For Medicare Advantage plans with drug coverage, the average Part D premium after rebates falls from $11.32 to $7. The release adds that 88% of beneficiaries who are not low-income can reach a basic Part D plan at $10.30 or less a month.

Medicare Advantage: 71% of members and 15 five-star contracts

Medicare Advantage plans with drug coverage, which CMS calls MA-PDs, score higher on this measure. CMS rated 508 MA-PD contracts for 2027, and 188 of them earned four stars or more, about 37%. Those contracts hold about 71% of members. The enrollment-weighted average rating is 3.99, against 4.01 for 2026, so the picture is steady rather than improving. Fifteen MA-PD contracts earned five stars and the high-performing icon, and six of them held it in 2026 as well.

At the other end, four MA-PD contracts carry the low-performing icon, the same count as last year. Nonprofit contracts did better than for-profit ones in Medicare Advantage: about 44% of nonprofit MA-PD contracts reached four stars, against about 34% of for-profit contracts. Among stand-alone drug plans the gap is a single point, 28% for nonprofit contracts and 27% for for-profit ones.

The ratings carry money for the insurers. The fact sheet says they affect Medicare Advantage quality bonus payments for 2028, and in April CMS’s 2027 rate announcement projected an increase of 2.48%, or over $13 billion, in payments to Medicare Advantage plans for the year. Those payments go to plans. A higher star rating does not lower a member’s premium or copay by itself, and the premium figures above come from a separate set of plan bids.

What the rating measures and what it leaves out

A Medicare Advantage plan with drug coverage can be graded on up to 43 measures, a Medicare Advantage plan without drug coverage on 32, and a stand-alone drug plan on 13. For 2027 CMS added two medication-safety measures, the concurrent use of opioids and benzodiazepines and the use of multiple anticholinergic medications in older adults. It also gave the physical health and mental health improvement measures a weight of three, and retired two Medicare Advantage measures, the pain assessment and the medication reconciliation after a hospital discharge.

Because the score belongs to a contract and not to a single plan, a member of one county’s plan shares a rating with every plan the same contract covers elsewhere. CMS also adjusted scores for extreme and uncontrollable circumstances in 2025, including the California wildfires and severe storms in Texas, and scaled down scores where it found data problems in the appeals records. Neither adjustment changes what a plan charges for a given drug.

Using the ratings before December 7

Open enrollment runs from October 15 to December 7. Medicare.gov says changes made in that window take effect January 1, and the plan must receive the request by December 7. Its open enrollment page lists what is allowed: joining, dropping or switching Medicare Advantage plans and stand-alone drug plans, or moving between Original Medicare and Medicare Advantage. CMS Administrator Dr. Mehmet Oz urged beneficiaries on September 28 to use the period to review their coverage and compare options.

For a member of a stand-alone drug plan, the new numbers work best as a tiebreaker. With 11 of 41 contracts at four stars or better, two plans that price the same prescriptions about the same may still differ on appeals handling and medication safety, which are among the graded measures. Moving from a three-star plan to a four-star plan gains little if the new plan prices a member’s main drug higher.

CMS’s own figures show how uneven the picture remains. About 71% of Medicare Advantage drug plan members are in four-star contracts and about 22% of stand-alone members are, and the enrollment-weighted averages of 3.99 and 3.22 leave more than three-quarters of a star between the two. Whether the jump from 2% to 22% proves lasting will show in next fall’s ratings, after CMS resets its cut points again.

Four stars says nothing about one prescription’s price

The detail that gets missed is that a star rating grades a contract’s quality, not what a particular drug costs on a particular plan. The 2027 Medicare Open Enrollment Decision Kit includes a cost calculator spreadsheet that compares plans on cost, drugs and doctors, so the plan with the higher rating can be set against the plan with the lower price before December 7.

Run the Part D cost calculator with the 2027 Open Enrollment Decision Kit before December 7 →

This article was prepared with AI assistance and reviewed against the cited public sources.


More in Social Security & Medicare